Jennison Associates’s CRISPR Therapeutics CRSP Stock Holding History

Jennison Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-409,683	Closed	-$31M	–	645
2021 Q4	$31M	Sell	409,683 -7,297	-2%	-$637K	0.02%	290
2021 Q3	$46.7M	Buy	416,980 +141,769	+52%	+$17.8M	0.03%	230
2021 Q2	$44.6M	Hold	275,211	–	–	0.03%	239
2021 Q1	$33.5M	Sell	275,211 -2,083	-0.8%	-$315K	0.02%	280
2020 Q4	$42.5M	Sell	277,294 -2,807	-1%	-$332K	0.03%	230
2020 Q3	$23.4M	Buy	280,101 +913	+0.3%	+$81K	0.02%	283
2020 Q2	$20.5M	Buy	279,188 +102,689	+58%	+$6M	0.02%	288
2020 Q1	$7.49M	Buy	+176,499	New	+$9.11M	0.01%	363
2018 Q4	–	Sell	-540,887	Closed	-$24M	–	661
2018 Q3	$24M	Buy	+540,887	New	+$28.3M	0.02%	369

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jennison Associates's CRSP Position: Q1 2022 in Review

Jennison Associates sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 409,683 shares — an estimated $31M sold.

Jennison Associates first reported a position in CRSP in Q3 2018 and held it in 9 quarters. The position peaked at $46.7M in Q3 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Jennison Associates reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Jennison Associates sold 409,683 CRISPR Therapeutics shares in Q1 2022, an estimated $31M.
Jennison Associates first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 9 quarters.
Jennison Associates's CRISPR Therapeutics position peaked at $46.7M in Q3 2021.
446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.